Dr. Agarwal's Health Care closes trading window for Q1FY27 results
Dr. Agarwal's Health Care has shut its trading window for designated persons effective June 30, 2026, in preparation for the unaudited financial results for the quarter ended June 30, 2026. The window will remain closed until the results are announced and will reopen 48 hours after the Board of Directors approves the figures.

*this image is generated using AI for illustrative purposes only.
Dr. Agarwal's Health Care has closed its trading window for all designated persons and their immediate relatives effective June 30, 2026. This closure is implemented to ensure compliance with its Code of Conduct for Prevention of Insider Trading as the company prepares to finalize and publish its unaudited financial results for the quarter ending June 30, 2026.
The restriction applies to dealings in the securities of the company and will remain in effect until the financial results are officially announced. The trading window is scheduled to reopen 48 hours after the Board of Directors approves and declares the unaudited financial results, which cover both standalone and consolidated figures.
Key Dates and Details
The following table outlines the critical timeline regarding the trading window closure and the upcoming financial announcement:
| Event | Date / Time |
|---|---|
| Trading Window Closure | June 30, 2026 |
| Quarter End | June 30, 2026 |
| Window Reopens | 48 hours after results announcement |
The company stated that the specific details regarding the board meeting to approve the results will be communicated in due course. This procedural step is standard practice to prevent insider trading while sensitive financial information is being finalized.
Historical Stock Returns for Dr. Agarwal's Health Care
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.20% | +7.39% | +3.37% | -5.75% | +15.78% | +17.58% |
What are the market's expectations for Dr. Agarwal's Health Care's standalone and consolidated financial performance for the quarter ending June 30, 2026?
How might the temporary trading restriction impact the stock's liquidity and volatility leading up to the results announcement?
Will the upcoming unaudited results provide any insights into the company's post-pandemic recovery strategy or expansion plans?

































